To view this email as a web page, click here

June 27, 2017

Subscribe

Our Team

Contact Us

FierceBiotech Logo

 

Today's Rundown

  1. Merck may file CETP candidate anacetrapib in unexpected turnaround

  2. Despite claims of 'looting,' Soon-Shiong’s NantCell set to buy Altor

  3. Xenon’s Teva-partnered pain drug flunks another test

  4. [Sponsored] Getting cancer vaccines right: Key challenges and solutions for neoantigen identification

  5. European biotech fund hits $74M, looks to build on previous successes

  6. NYC Mayor de Blasio puts up first cash for ambitious life sciences project

  7. Mitoconix Bio hits $20M series A for neurodegenerative R&D

  8. NYU scientists zero in on mechanism for removing plaque from arteries

  9. Georgian, Insulet, Mayo Clinic get in on Glooko’s $35M series C

  10. AstraZeneca's struggling FluMist loses out on crucial CDC vaccine backing—again

Featured Story

Merck may file CETP candidate anacetrapib in unexpected turnaround

Hit by trial setbacks and failures that have blighted the entire class, Merck is mulling whether to file its cholesteryl ester transfer protein (CETP) medication anacetrapib after posting some surprising positive topline data from the Reveal test.

Top Stories

Despite claims of 'looting,' Soon-Shiong’s NantCell set to buy Altor

Controversial billionaire biotech entrepreneur Patrick Soon-Shiong and his outfit NantCell say it will acquire Altor Bioscience for two bucks a share, plus a weighted CVR.

Xenon’s Teva-partnered pain drug flunks another test

It’s another hard luck story for Xenon and partner Teva’s experimental pain drug TV-45070 after missing a full set of endpoints in patients with pain following shingles.

[Sponsored] Getting cancer vaccines right: Key challenges and solutions for neoantigen identification

Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.

European biotech fund hits $74M, looks to build on previous successes

The third BioGeneration Ventures Fund has gone over its €50 million target and hit €66 million ($74 million) as it attracts new investors.

NYC Mayor de Blasio puts up first cash for ambitious life sciences project

New York City's bid to become a life sciences hotspot took another step forward this week with the help of a $5 million grant from the mayor's office.

Mitoconix Bio hits $20M series A for neurodegenerative R&D

Preclinical startup Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders, including its lead candidate for Huntington’s disease.

NYU scientists zero in on mechanism for removing plaque from arteries

Low-density lipoprotein is commonly called “bad cholesterol” because it builds up along the walls of the arteries, forming plaques that can cause deadly blockages. A new finding by scientists at NYU shows how a key player in that inflammatory process switches roles, becoming a healing influence instead.

Georgian, Insulet, Mayo Clinic get in on Glooko’s $35M series C

Digital diabetes management player Glooko has been on a roll and is showing no signs of stopping. The company has picked up $35 million to further develop its technology and expand in a number of geographic regions.

AstraZeneca's struggling FluMist loses out on crucial CDC vaccine backing—again

Last June, a key CDC vaccines committee stiff-armed AstraZeneca's nasal influenza vaccine based on worries about its effectiveness. Despite the company's efforts to fix things since then, the committee once again recommended that doctors eschew FluMist for the upcoming flu season.

News of Note

It's name-change day, as RaNA Therapeutics has relaunched as Translate Bio, coming after its recent Shire deal. Statement

Cancer company Lion Biotechnologies has changed its name to Iovance Biotherapeutics with a new Nasdaq ticker symbol "IOVA" to boot. Release

Hoping to compete with Big Pharma rivals, Alder has posted new positive phase 3 data for eptinezumab in preventing frequent episodic migraine. Statement

Resources

[Whitepaper] Make Your Clinical Trials a Success

Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more.

[Whitepaper] Enable better radiation therapy study results

Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models.

[Webinar] Going Digital: Connecting Submission Documents and Regulatory Data

Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems.

[Webinar] Outsourcing complex microsurgeries – is it worth the risk?

Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

[Webinar] Leveraging Medical Insights for Better Healthcare Engagement

Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape.

[Whitepaper] The Paperless Future of Healthcare and Life Sciences

DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors.

[Whitepaper] DocuSign Life Sciences eBook: Reducing Cycle Time with Digital Transaction Management

The patients who rely on your scientific leadership are expecting more.

[Whitepaper] Streamline Regulatory Compliance in Life Sciences with Digital Transaction Management

The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company.

Events

.